New study aims to uncover why catheters cause blood clots
NCT ID NCT07014722
First seen Jun 27, 2026 · Last updated Sep 17, 2026 · Updated 2 times
Summary
This study looks at how four types of central venous catheters (thin tubes placed in large veins) affect the body's clotting system. Researchers will take blood samples from 88 adults right after catheter insertion and again after flushing, to measure clotting changes. The goal is to understand why clots form and help make catheters safer.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
88 people
The number who actually took part.
- Started
-
Sep 2025
- Finished
-
Aug 2026
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria Participants must meet all of the following criteria to be included in the study: 1. Clinical indication for the placement of a two-lumen central venous catheter with length 150-160 mm. 2. Age ≥18 years. 3. Signed informed consent. Exclusion Criteria Participants meeting any of the following criteria will be excluded: 1. Current use of anticoagulants or platelet inhibitors, except: Prophylactic low molecular weight heparin (LMWH), double prophylactic dose of LMWH, Acetylsalicylic acid (ASA). 2. Prothrombin complex (pK/INR) outside the normal range (0.9-1.2), platelet count \<50 × 10⁹/L or haemoglobin \< 80 g/L, if already available. 3. Known coagulopathic conditions, including but not limited to: * Activated protein C (APC) resistance, * Hemophilia A or B, * Vitamin K deficiency, * Disseminated intravascular coagulation (DIC), * Antiphospholipid syndrome, * von Willebrand disease, Other known congenital or acquired bleeding disorders.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Central venous catheter are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Skåne University Hospital Lund
Lund, Skåne County, 22242, Sweden
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can ultrasound predict difficult IV insertions before they happen?
- Common ICU procedure may briefly raise brain pressure — study investigates the risk
- Frail heart patients may need extra care for routine IV placement, study suggests
- Which dressing best protects skin from medical adhesive injury in ICU patients?
- Laughing gas takes on the needle: could a simple breath ease one of Medicine's most uncomfortable procedures?
- New study to define healthy blood clotting ranges for kids